Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + piperaquine phosphate
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antimalarial therapy consisting of azithromycin (a macrolide antibiotic) and piperaquine phosphate (a bisquinoline antimalarial). This combination has been studied for the treatment and prevention of malaria, particularly in pregnant women. Azithromycin inhibits bacterial protein synthesis by binding to the 23S rRNA of the bacterial 50S ribosomal subunit[7], while piperaquine inhibits the Plasmodium falciparum parasite's haem detoxification pathway, similar to chloroquine[9]. The combination shows promising efficacy and tolerability, with no evidence of increased cardiotoxicity compared to either drug alone[1].
- Other names
- azithromycin plus piperaquineazithromycin plus piperaquine phosphate
02
Targets
23S rRNA (23S ribosomal RNA)Hemeβ-Hematin
Beyond the preview
Go deeper on azithromycin + piperaquine phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + piperaquine phosphate.